Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
Dose-reduced busulfan, cyclophosphamide, and autologous stem cell transplantation for human immunodeficiency virus-associated lymphoma: AIDS Malignancy Consortium study 020.
复制标题
减少剂量白消安、环磷酰胺和自体干细胞移植治疗人类免疫缺陷病毒相关淋巴瘤：艾滋病恶性肿瘤联盟研究 020。
DOI：
10.1016/j.bbmt.2007.03.014
复制
发表时间：
2008
期刊：
影响因子：
--
通讯作者：
Scadden,DavidT
中科院分区：
文献类型：
--
作者：
Spitzer,ThomasR;Ambinder,RichardF;Lee,JeannetteY;Kaplan,LawrenceD;Wachsman,William;Straus,DavidJ;Aboulafia,DavidM;Scadden,DavidT
人类免疫缺陷病毒（HIV）相关非霍奇金淋巴瘤（NHL）和霍奇金淋巴瘤（HL）的强化化疗已导致相当大比例的患者获得持久缓解。此外，高剂量化疗和自体干细胞移植（AuSCT）已导致选定的复发性化疗敏感性疾病患者持续完全缓解。基于减少剂量的高剂量白消安、环磷酰胺和AuSCT治疗老年非HIV相关侵袭性淋巴瘤患者的有利经验，AIDS联盟进行了一项多中心试验，使用相同的减少剂量的白消安和环磷酰胺准备方案与AuSCT治疗复发性HIV相关NHL和HL。在该研究的27名患者中，20名接受了AuSCT。至中性粒细胞绝对计数（ANC）≥ 0.5×109/L的中位时间为11天（范围：9-16天）。达到无支持血小板计数≥ 20×109/L的中位时间为13天（范围：6-57天）。1例患者在移植后第+33天死于肝静脉闭塞性疾病（VOD）和多器官衰竭。未发生其他致死性方案相关毒性。19例患者中有10例（53%）在AuSCT后第+100天评价时完全缓解。在20例患者中，10例患者在AuSCT后中位23周时存活且无事件。末次随访时，20例存活患者中有13例未达到中位总生存期（OS）。这项多机构试验表明，剂量降低的高剂量白消安、环磷酰胺和AuSCT方案耐受性良好，并且与选定的HIV相关NHL和HL患者的无病生存期（DFS）和OS概率相关。
Intensive chemotherapy for human immunodeficiency virus (HIV)-associated non-Hodgkin lymphoma (NHL) and Hodgkin lymphoma (HL) has resulted in durable remissions in a substantial proportion of patients. High-dose chemotherapy and autologous stem cell transplantation (AuSCT), moreover, has resulted in sustained complete remissions in selected patients with recurrent chemosensitive disease. Based on a favorable experience with dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT for older patients with non-HIV–associated aggressive lymphomas, an AIDS Malignancy Consortium multicenter trial was undertaken using the same dose-reduced busulfan and cyclophosphamide preparative regimen with AuSCT for recurrent HIV-associated NHL and HL. Of the 27 patients in the study, 20 received an AuSCT. The median time to achievement of an absolute neutrophil count (ANC) of ≥ 0.5×109/L was 11 days (range, 9-16 days). The median time to achievement of an unsupported platelet count of ≥ 20×109/L was 13 days (range, 6-57 days). One patient died on day +33 posttransplantation from hepatic veno-occlusive disease (VOD) and multiorgan failure. No other fatal regimen-related toxicity occurred. Ten of 19 patients (53%) were in complete remission at the time of their day +100 post-AuSCT evaluation. Of the 20 patients, 10 were alive and event-free at a median of 23 weeks post-AuSCT. Median overall survival (OS) was not reached by 13 of the 20 patients alive at the time of last follow-up. This multi-institutional trial demonstrates that a regimen of dose-reduced high-dose busulfan, cyclophosphamide, and AuSCT is well tolerated and is associated with favorable disease-free survival (DFS) and OS probabilities for selected patients with HIV-associated NHL and HL.
登录
查看更多内容
HIV相关淋巴瘤：有希望的新结果，但具有毒性。
影响因子：
20.3
作者：
D. Straus
通讯作者：
D. Straus
白消安和环磷酰胺 (BU/CY2) 作为淋巴瘤患者的准备方案
影响因子：
4.8
作者：
M. deMagalhaes;John Lister;W. Rybka;John W. Wilson;Edward D. Ball
通讯作者：
Edward D. Ball
剂量调整静脉注射白消安/环磷酰胺 (BU/CY) 和自体 (AU) 干细胞移植 (SCT) 治疗复发性淋巴瘤。
DOI：
--
发表时间：
2004
期刊：
影响因子：
--
作者：
T. Spitzer;Benjamin F. Cox;P. Sepe;S. Mcafee;B. Dey;K. Ballan;D. Scadden
通讯作者：
D. Scadden
影响因子：
4.8
作者：
Kiss, TL;Panzarella, T;Lipton, JH
通讯作者：
Lipton, JH
影响因子：
45.3
作者：
Re, A;Cattaneo, C;Rossi, G
通讯作者：
Rossi, G